Fasenra

Fasenra

Manufacturer:

AstraZeneca

Distributor:

Zuellig
/
Four Star
Concise Prescribing Info
Contents
Benralizumab
Indications/Uses
Add-on maintenance treatment in adult patients w/ severe eosinophilic asthma, inadequately controlled despite high-dose inhaled corticosteroids plus long-acting β-agonists.
Dosage/Direction for Use
SC 30 mg every 4 wk for the 1st 3 doses, then every 8 wk thereafter.
Contraindications
Special Precautions
Reports of hypersensitivity reactions (eg, urticaria, papular urticaria, rash) following Fasenra administration. Should not be used to treat acute asthma exacerbations. Seek medical advice if asthma remains uncontrolled or worsens after initiation of treatment. Abrupt discontinuation of corticosteroids after inititation of Fasenra therapy is not recommended. Patients w/ pre-existing helminth infections. Pregnancy & lactation. Childn ≤18 yr.
Adverse Reactions
Pharyngitis; headache; hypersensitivity reactions; pyrexia, inj site reactions.
ATC Classification
R03DX10 - benralizumab ; Belongs to the class of other systemic drugs used in the treatment of obstructive airway diseases.
Presentation/Packing
Form
Fasenra soln for inj 30 mg/mL
Packing/Price
1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in